Skip to content

The EPA Is Still Approving Pesticides Linked To Breast Cancer

The EPA has many serious problems, from protecting corporations and not consumers, to ignoring studies that find health problems with products or chemicals. Dr. Jennifer Liss Ohayon, a research scientist at Silent Spring Institute and Northeastern University, pointed out in a recent article that the EPA keeps approving pesticides linked to breast cancer.

These pesticides act as endocrine disruptors on the breast, with effects occurring at low doses. Many are commonly used (e.g., malathion, atrazine), which means women are exposed to in food, water, the workplace, and at home (yes - home, garden, and lawn chemicals!).

Why be concerned? Young women are experiencing earlier breast development, difficulty in breastfeeding, and increasing rates of breast cancer. Many studies link this in women (and in animals) with chemical exposures, especially endocrine disrupting chemicals (this is because they screw with hormones, and so have an effect on breast development and breast tissue).

But... the EPA is dismissing or ignoring relevant studies and pooh poohing the idea that chemicals can have harmful endocrine disrupting effects. Effects on the breast (mammary gland) are NOT required to be part of the EPA's chemical risk assessment (which determines whether a pesticide will be approved). The studies the EPA relies on are almost all financed by the manufacturers (hmmm...of course they'll say the pesticide is safe).

Note that the European Union bans many of the worrisome pesticides - they are not ignoring the science, and in doing so protect people.

From a piece by Dr Jennifer Liss Ohayon at Environmental Health News (EHN): Why is the EPA still exposing women to pesticides linked to breast cancer?

This fall marks the 60th anniversary of writer and scientist Rachel Carson’s 1962 book “Silent Spring.” The book was seminal in that it sparked the modern environmental movement, a U.S. ban of DDT, and the founding of the Environmental Protection Agency (EPA). However, despite decades passing since Carson first warned us about the dangers of pesticides, EPA continues to approve pesticides linked to breast cancer.

A recent peer-reviewed study by my colleagues at the Silent Spring Institute, a scientific research organization named in Carson’s honor, found that regulators routinely fail to consider the risk that a pesticide might cause breast cancer when approving its use.

Typically, when a manufacturer seeks EPA approval for a pesticide, it submits studies that address the potential for the pesticide to cause cancer. Using the EPA's pesticide registration documents, my colleagues identified 28 pesticides linked with mammary tumors in those studies. For 19 of these pesticides, the EPA dismissed the evidence altogether and only acknowledged nine of them as causing mammary tumors.

The pesticides are commonly used as preservatives in cosmetics, food, and pharmaceuticals and as agricultural and residential herbicides. Yet in its evaluations, the EPA provided either no reason or vague rationales for dismissing the tumors. Many of the pesticides are not approved for use in the European Union.

As we head into breast cancer awareness month, we are reminded of breast cancer’s enormous toll. Breast cancer remains one of the few cancers that continues to increase in prevalence. Not only is it the most commonly diagnosed cancer, surpassing lung cancer, rates among U.S. women under the age of 40 are on the rise.

In order to bring down incidence rates, it's imperative that we address the preventable causes of breast cancer, and that includes catching cancer-causing chemicals before people are exposed.

To identify breast carcinogens, we need to account for the multiple ways that chemicals can trigger the development of cancer. For instance, many of the pesticides reviewed in the Silent Spring Institute study act like endocrine disruptors, which can alter mammary gland development and increase breast cancer risk.

In another peer-reviewed study, the same team of scientists identified nearly 300 chemicals, including a number of pesticides, that cause cells to produce more of the hormones estrogen or progesterone—known risk factors for breast cancer.

The science of endocrine disrupting chemicals has advanced. And although testing has been updated to detect the effects of chemicals on the developing reproductive system, effects on the developing mammary gland are not required to be part of the EPA’s chemical risk assessments. This is a terrible oversight that limits the agency’s ability to identify chemicals that disrupt breast development and lactation, and increase the risk of breast cancer. In a new review article, my colleagues at Silent Spring outline different ways in which regulators could improve outdated testing methods, and therefore their ability to prioritize chemicals for regulation.

In 1970, a newly created EPA was tasked with handling approval and restrictions of pesticides in the hopes of diminishing the influence of the agricultural lobby over the regulatory process. Unfortunately, allegiance to industry interests and corruption within the agency persist.

Recent investigations have found the EPA guilty of downplaying or deleting hazards in scientific evaluations of the safety of pesticides and other chemicalswaiving toxicity tests, creating a culture of intimidation toward staff scientists who raise concerns, and greasing a revolving door between the agency and the agrochemical industry. The agency almost solely relies on industry-led studies when approving pesticides, and often does not have the resources or time to scrutinize the data.

While it would be useful for independent researchers to evaluate information in the underlying studies that EPA used to report on the safety of pesticides, these are not usually publicly available without a granted Freedom of Information request, and that can take many months or longer to obtain.

The EPA must update its carcinogenicity and reproductive testing guidelines to better capture the effects of pesticides on the mammary gland, including the effects of endocrine disruptors, and make underlying studies freely available so that they may be evaluated by independent researchers. Importantly, the EPA needs to stop relying heavily on industry-financed studies in the first place.

EPA also must reevaluate its cancer risk assessments of five approved pesticides—malathion, triclopyr, atrazine, propylene oxide, and 3-iodo-2-propynyl butylcarbamate—given their widespread use and strong evidence of harm.

Leave a Reply

Your email address will not be published. Required fields are marked *